582 related articles for article (PubMed ID: 26970489)
1. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
2. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
4. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D
Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab and Other CD20
Gelfand JM; Cree BAC; Hauser SL
Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
[TBL] [Abstract][Full Text] [Related]
6. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
7. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
9. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
10. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
11. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
13. [B-cell Depletion Therapy in Multiple Sclerosis].
Miyazaki Y; Niino M
Brain Nerve; 2018 Nov; 70(11):1289-1294. PubMed ID: 30416122
[TBL] [Abstract][Full Text] [Related]
14. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
Trebst C; Voss E; Skripuletz T; Stangel M
Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibodies in multiple sclerosis.
Moreno Torres I; García-Merino A
Expert Rev Neurother; 2017 Apr; 17(4):359-371. PubMed ID: 27718747
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.
Menge T; Dubey D; Warnke C; Hartung HP; Stüve O
Expert Rev Neurother; 2016 Oct; 16(10):1131-9. PubMed ID: 27552111
[TBL] [Abstract][Full Text] [Related]
18. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.
Bittner S; Ruck T; Wiendl H; Grauer OM; Meuth SG
Ther Adv Neurol Disord; 2017 Jan; 10(1):51-66. PubMed ID: 28450895
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
20. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C; Haggiag S; Ruggieri S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]